{"id":"NCT00316706","sponsor":"GlaxoSmithKline","briefTitle":"Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine","officialTitle":"A Long-term, Open Follow-up of the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine (580299) in Healthy Female Subjects Vaccinated in Study HPV-013","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-10","primaryCompletion":"2009-01","completion":"2009-01","firstPosted":"2006-04-21","resultsPosted":"2010-03-01","lastUpdate":"2012-09-18"},"enrollment":1245,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Cervical Intraepithelial Neoplasia","Papillomavirus Infection"],"interventions":[{"type":"BIOLOGICAL","name":"GSK Biologicals' HPV-16/18 Vaccine (Cervarix™)","otherNames":[]},{"type":"BIOLOGICAL","name":"Havrix™","otherNames":[]}],"arms":[{"label":"Cervarix Group","type":"EXPERIMENTAL"},{"label":"Havrix Group","type":"ACTIVE_COMPARATOR"}],"summary":"This protocol posting deals with objectives \\& outcome measures of the extension phase up to Month 48. The objective of the extension study is to evaluate the long-term immunogenicity of the HPV 16/18 L1 VLP AS04 vaccine (for all subjects in the HPV Vaccine Group) by enzyme-linked immunosorbent assay (ELISA). The objectives \\& outcome measures of the primary phase are presented in a separate protocol posting (NCT00196924).\n\nThe long-term follow-up study will be blinded until the primary study is unblinded and will be open for all visits subsequent to unblinding of primary study HPV-013 (NCT00196924). During the open phase, only subjects who received the HPV-16/18 VLP/AS04 vaccine during the primary study will continue their participation in the follow-up study until Month 48. Subjects in the Control group (Havrix®) will attend one further visit as their last study visit.\n\nThe Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.","primaryOutcome":{"measure":"Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies","timeFrame":"At 18, 24, 36 and 48 months","effectByArm":[{"arm":"Cervarix Group","deltaMin":3901.6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"10 Years","sex":"FEMALE","healthyVolunteers":true,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":28,"countries":["Colombia","Germany","Honduras","Panama","Taiwan"]},"refs":{"pmids":["22265115"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":33,"n":626},"commonTop":[]}}